Data Insights

By Company Name

By Disease Name

By Drug Name

By Themes

Showing 5 results out of 5

Company Profiles

Access comprehensive reports covering all the major players in the pharmaceutical industry

Gain a competitive edge
Enhance your sales strategy
Get forward-looking insights
Support your decision making

Buy Now

Data Insights

Nizubaglustat by Azafaros for Tay-Sachs Disease: Likelihood of Approval

Nizubaglustat is under clinical development by Azafaros and currently in Phase I for Tay-Sachs Disease. According to GlobalData, Phase I...

Data Insights

Nizubaglustat by Azafaros for Sandhoff Disease (Jatzkewitz-Pilz Syndrome): Likelihood of Approval

Nizubaglustat is under clinical development by Azafaros and currently in Phase I for Sandhoff Disease (Jatzkewitz-Pilz Syndrome). According to GlobalData,...

Data Insights

Nizubaglustat by Azafaros for Niemann-Pick Disease Type C: Likelihood of Approval

Nizubaglustat is under clinical development by Azafaros and currently in Phase II for Niemann-Pick Disease Type C. According to GlobalData,...

Data Insights

Nizubaglustat by Azafaros for GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency): Likelihood of Approval

Nizubaglustat is under clinical development by Azafaros and currently in Phase I for GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency). According...

Data Insights

Nizubaglustat by Azafaros for Tay-Sachs Disease: Likelihood of Approval

Nizubaglustat is under clinical development by Azafaros and currently in Phase I for Tay-Sachs Disease. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Nizubaglustat in Tay-Sachs Disease